Avadel Pharmaceuticals plc
AVDL
$0.20
Change (1 day)
$19.09
Year High
$9.41
Year Low
Categories
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
P/E ratio for Avadel Pharmaceuticals plc (AVDL)
P/E ratio as of 2023: -7.06
According to Avadel Pharmaceuticals plc's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.06. At the end of 2022 the company had a P/E ratio of -3.13.
P/E ratio history for Avadel Pharmaceuticals plc from 1996 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.06 |
| 2022 | -3.13 |
| 2021 | -6.12 |
| 2020 | 50.37 |
| 2019 | -8.50 |
| 2018 | -1.01 |
| 2017 | 4.93 |
| 2016 | -10.38 |
| 2015 | 12.19 |
| 2014 | -7.31 |
| 2013 | -4.77 |
| 2012 | -23.42 |
| 2011 | -14.65 |
| 2010 | -18.60 |
| 2009 | -15.67 |
| 2008 | -7.81 |
| 2007 | -6.35 |
| 2006 | -20.26 |
| 2005 | -15.86 |
| 2004 | 33.55 |
| 2003 | -136.19 |
| 2002 | 23.45 |
| 2001 | -15.33 |
| 2000 | -10.63 |
| 1999 | -4.12 |
| 1998 | -6.75 |
| 1997 | -2.78 |
| 1996 | -9.38 |